Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

EG110A

Phase 2Small molecule

2

Indications

2

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neurogenic Detrusor OveractivityRecruiting

Herpes Simplex VirusNot yet recruiting

Neurogenic Detrusor OveractivityPreclinical

Recruiting

Herpes Simplex VirusPhase 2

Not yet recruiting

Timeline

Expected Milestones

Q2 2027

PreclinicalRecruiting

Neurogenic Detrusor Overactivity

NCT06596291

Q2 2031

Phase 1/2Not yet recruiting

Herpes Simplex Virus

NCT07227285

Clinical

Trials by Indication[1]

Herpes Simplex Virus1 trial

Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy

Not yet recruiting·EEG 427·Phase 1/2·NCT07227285·16 enrolled

Neurogenic Detrusor Overactivity1 trial

First-In-Human Phase 1b/2a Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adult Participants With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization

Recruiting·EEG 427·Preclinical·NCT06596291·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for EG110A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EG110A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EG110A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EG 427 company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEG 427

Related News